Cannabidiol 相關新聞
Cannabidiol 目前有 0 則相關新聞報導,預測適應症 20 個。
本頁整合 Cannabidiol 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and...
- 證據等級:L5
- 預測適應症(20 個):
- restless legs syndrome(96.2%)
- bilateral parasagittal parieto-occipital polymicrogyria(96.0%)
- axial spondylometaphyseal dysplasia(94.2%)
- amyotrophic lateral sclerosis(94.2%)
- trichomegaly-retina pigmentary degeneration-dwarfism syndrome(93.8%)
- episodic kinesigenic dyskinesia(93.7%)
- Mills syndrome(93.4%)
- amyotrophic lateral sclerosis, susceptibility to(93.4%)
- lower motor neuron syndrome with late-adult onset(93.2%)
- lethal arthrogryposis-anterior horn cell disease syndrome(93.2%)
- monomelic amyotrophy(93.1%)
- amyotrohpic lateral sclerosis type 22(92.9%)
- PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation(92.4%)
- neonatal period electroclinical syndrome(92.3%)
- 1q44 microdeletion syndrome(92.2%)
- myoclonic epilepsy, Hartung type(92.0%)
- developmental and epileptic encephalopathy(92.0%)
- genetic lethal multiple congenital anomalies/dysmorphic syndrome(91.9%)
- autosomal dominant mitochondrial myopathy with exercise intolerance(91.9%)
- infancy electroclinical syndrome(91.8%)
相關新聞(0 則)
目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。